On the 24th October NDA Group invites you and your colleagues in the market access department/HEOR to a complimentary seminar on the future of HTA.
The market access environment is getting increasingly challenging. The ability to develop plans and strategies for access, for today as well as tomorrow, is critical to bring new medicines to patients.
With 17 years as Executive Director for NICE, Carole Longson has unparalleled experience in understanding how HTA bodies work and collaborate in the EU. In June 2018 she joined NDA as a HTA Advisor.
This seminar will discuss the past, present and future of HTA and market access. On stage Carole is joined by an esteemed panel comprising Dr Steffen Thirstrup, former Division Head at the Danish Medicines Agency and CHMP member, Dr Fredrik Andersson, Senior Director Global HEOR Ferring and Mark Aagren, Senior Director Market Access and Public Affairs ALK.
Date: 24 October 2018
Time: 8:30 – 12:00
Venue: Medicon Valley Alliance, Arne Jacobsens Alle 15 , 2300 Ørestad City, Copenhagen, Denmark, Ground floor
Registration & light breakfast
Session 1 – Challenges on development programs for new drugs
Session 2 – HTA alignment in Europe – what does the future of HTA have in store?
Conversation leaders at stage:
End of meeting – conclusions and take-home messages
12:00 – 1400
Ask the Experts
About NDA Group
NDA Group is a world leading drug development consultancy. Over the past five years NDA has supported over 40% of the new medicinal products approved in Europe.
In collaboration with: